PMID: 30794363Feb 23, 2019Paper

Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib

Journal of Drugs in Dermatology : JDD
Jennifer C. TangC William Hanke

Abstract

Background: Vismodegib used in the treatment of metastatic basal cell carcinoma (BCC) or locally advanced, recurrent BCC not amenable to surgery or radiation leads to various clinical changes. Objective: Aim was to elucidate the histopathology that corresponds to tumor involution observed with vismodegib therapy. Methods: Retrospective case series of patients treated with vismodegib between May 2012 and April 2017 with intra- or post-treatment biopsy. Results: 42 biopsy specimens and 4 Mohs frozen sections were analyzed. Necrosis, fibrosis, and increased plasma cells were common features. Limitations: Single center study. Conclusion: The histologic findings of BCCs treated with vismodegib correlate with clinical response. J Drugs Dermatol. 2019;18(2):136-138.

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]
Emily M PowellTravis W Blalock
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]
Bishr AldabaghS T Arron
Journal of the American Academy of Dermatology
N R Friedman
© 2022 Meta ULC. All rights reserved